327 related articles for article (PubMed ID: 21176358)
41. Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression.
Cao X; Medeiros LJ; Xia Y; Wang X; Thomas SK; Loghavi S; Li X; Shah JJ; Gustafson SA; Weber DM; Miranda RN; Xu-Monette ZY; Orlowski RZ; Young KH
Leuk Lymphoma; 2016 May; 57(5):1104-13. PubMed ID: 26421453
[TBL] [Abstract][Full Text] [Related]
42. Waldenstrom macroglobulinemia presenting with pancreatic mass: a case report and review of literature.
Nayak HK; Kar P; Bagchi A; Kapoor N; Kapahtia S; Sonika U; Kumar N; Kumar S
JOP; 2013 Jan; 14(1):92-5. PubMed ID: 23306344
[TBL] [Abstract][Full Text] [Related]
43. Role of plasma cells in Waldenström macroglobulinaemia.
El-Ayoubi A; Wang JQ; Hein N; Talaulikar D
Pathology; 2017 Jun; 49(4):337-345. PubMed ID: 28483372
[TBL] [Abstract][Full Text] [Related]
44. [Waldenström macroglobulinemia. Experience in 31 patients].
Cardemil D; León P; Peña C; Valladares X; Cabrera ME
Rev Med Chil; 2019 Mar; 147(3):275-280. PubMed ID: 31344163
[TBL] [Abstract][Full Text] [Related]
45. MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity.
Schmidt J; Federmann B; Schindler N; Steinhilber J; Bonzheim I; Fend F; Quintanilla-Martinez L
Br J Haematol; 2015 Jun; 169(6):795-803. PubMed ID: 25819228
[TBL] [Abstract][Full Text] [Related]
46. VS38 staining contributes to a novel gating strategy in flow cytometry for small B cell lymphoma, especially in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.
Mizuta S; Yamane N; Mononobe S; Watanabe A; Matsuki S; Komai T; Koba Y; Mitani S; Kawata T; Tamekane A; Watanabe M
Cytometry B Clin Cytom; 2022 Jan; 102(1):50-61. PubMed ID: 33682304
[TBL] [Abstract][Full Text] [Related]
47. A minority of concurrent monoclonal lymphocytes and plasmacytic cells sharing light chains are genetically related in putative lymphoplasmacytic lymphoma.
Zehentner BK; Cutler JA; Fritschle WK; Bennington RK; Wentzel C; Smading SR; Jeffery EW; Wells DA; Loken MR
Leuk Res; 2011 Dec; 35(12):1597-604. PubMed ID: 21752465
[TBL] [Abstract][Full Text] [Related]
48. The Bone Marrow Microenvironment in Waldenström Macroglobulinemia.
Jalali S; Ansell SM
Hematol Oncol Clin North Am; 2018 Oct; 32(5):777-786. PubMed ID: 30190017
[TBL] [Abstract][Full Text] [Related]
49. Despite apparent morphologic and immunophenotypic heterogeneity, Waldenstrom's macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells.
Remstein ED; Hanson CA; Kyle RA; Hodnefield JM; Kurtin PJ
Semin Oncol; 2003 Apr; 30(2):182-6. PubMed ID: 12720133
[TBL] [Abstract][Full Text] [Related]
50. Waldenström macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors.
Owen RG; Barrans SL; Richards SJ; O'Connor SJ; Child JA; Parapia LA; Morgan GJ; Jack AS
Am J Clin Pathol; 2001 Sep; 116(3):420-8. PubMed ID: 11554171
[TBL] [Abstract][Full Text] [Related]
51. Defining Lymphoplasmacytic Lymphoma: Does MYD88L265P Define a Pathologically Distinct Entity Among Patients With an IgM Paraprotein and Bone Marrow-Based Low-Grade B-Cell Lymphomas With Plasmacytic Differentiation?
Fang H; Kapoor P; Gonsalves WI; Frederick LA; Viswanatha D; Howard MT; He R; Morice WG; McPhail ED; Greipp PT; Ansell SM; Kyle RA; Gertz MA; Paludo J; Abeykoon J; King RL
Am J Clin Pathol; 2018 Jul; 150(2):168-176. PubMed ID: 29868855
[TBL] [Abstract][Full Text] [Related]
52. Are you sure this is Waldenstrom macroglobulinemia?
Ghobrial IM
Hematology Am Soc Hematol Educ Program; 2012; 2012():586-94. PubMed ID: 23233639
[TBL] [Abstract][Full Text] [Related]
53. Cryoglobulinemia as a Possible Primer for TRALI: Report of a Case.
Beech C; Kumar D; Hendrickson J; Perincheri S; Tormey C; Bahar B
Lab Med; 2019 Jul; 50(3):313-319. PubMed ID: 30657960
[TBL] [Abstract][Full Text] [Related]
54. Bing-Neel syndrome: Two unexpected cases and a review of the literature.
Van Cauwenberge MG; Depreter B; Dumoulin EN; Emmerechts J; Nollet F; Vanopdenbosch LJ
J Neurol Sci; 2015 Sep; 356(1-2):19-26. PubMed ID: 26159625
[TBL] [Abstract][Full Text] [Related]
55. Clinicopathological features and individualized treatment of kidney involvement in B-cell lymphoproliferative disorder.
Nie G; Sun L; Zhang C; Yuan Y; Mao H; Wang Z; Li J; Duan S; Xing C; Zhang B
Front Immunol; 2022; 13():903315. PubMed ID: 36172352
[TBL] [Abstract][Full Text] [Related]
56. Clinical features and treatment outcomes of lymphoplasmacytic lymphoma: a single center experience in Korea.
Won YW; Kim SJ; Kim K; Ko YH; Kim WS
Ann Hematol; 2010 Oct; 89(10):1011-8. PubMed ID: 20449747
[TBL] [Abstract][Full Text] [Related]
57. A review of Waldenstrom's macroglobulinemia.
McDermott MK; Bell EM
Clin J Oncol Nurs; 1999 Jul; 3(3):107-11. PubMed ID: 10690041
[TBL] [Abstract][Full Text] [Related]
58. Waldenström macroglobulinemia treatment algorithm 2018.
Gertz MA
Blood Cancer J; 2018 May; 8(4):40. PubMed ID: 29712895
[TBL] [Abstract][Full Text] [Related]
59. Detection of MYD88 L265P mutations in formalin-fixed and decalcified BM biopsies from patients with lymphoplasmacytic lymphoma.
Capaldi IB; May AM; Schmitt-Graeff A; Follo M; Aumann K; Kayser G; Perazzo JC; Werner M; Fisch P
Exp Mol Pathol; 2014 Aug; 97(1):57-65. PubMed ID: 24842316
[TBL] [Abstract][Full Text] [Related]
60. Waldenström's macroglobulinemia: a clinicopathologic study of 22 cases.
Andriko JA; Aguilera NS; Chu WS; Nandedkar MA; Cotelingam JD
Cancer; 1997 Nov; 80(10):1926-35. PubMed ID: 9366295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
